Tag Archives: COVID-19 therapy cuts deaths among hospitalised patients who lack antibodies

LONDON: Regeneron Pharmaceuticals’ COVID-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found. The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate COVID-19 in the United States, but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised …

Read More »